clinical trials

Pracinostat

Study NoStudy TitleNo. of PatientsStatus
MEI-003Phase 2 Study of Pracinostat with Azacitidine in Patients with Previously Untreated Myelodysplastic Syndrome
ClinicalTrials.gov
100Recruiting
MEI-004Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
ClinicalTrials.gov
40 evaluableRecruiting
MEI-005Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
ClinicalTrials.gov
Up to 76Recruiting
MEI-006Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects
ClinicalTrials.gov
28Active, Not Recruiting
MEI-007Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects
ClinicalTrials.gov
32Recruiting
2010-0319Study of SB939 in Subjects with Myelofibrosis
Quintás Crdama, et al. Leukemia Research (2012) [ Paper ]
22Completed
SB939-2007-002SB939 in Treating Patients with Locally Advanced or Metastatic Solid Tumors
Razak, et al. British Journal of Cancer (2011) [ Paper ]
38Completed
SB939-2006-001A Phase I Dose Escalation Study of Oral SB939 Administered Alone or with Azacitidine  
 Arm A: Advanced Solid Tumors
Yong, et al. Annals of Oncology (2011) [ Paper ]
30Completed
 Arm B: Advanced Hematologic Malignancies
Garcia-Manero, et al. ASH Annual Meeting (2010) [ Poster ]
44Completed
 Arm C: Myelodysplastic Syndrome
Quintás Cardama, et al. ASH Annual Meeting (2012) [ Poster ]
9Completed

ME-344

Study NoStudy TitleNo. of PatientsStatus
ME-344-001Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
Bendell, et al. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2013) [ Poster ]
30Active, Not Recruiting
ME-344-002ME-344 Given in Combination with Hycamtin® in Patients with Solid Tumors
ClinicalTrials.gov
Up to 64Recruiting

ME-143

Study NoStudy TitleNo. of PatientsStatus
ME-143-001Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors
Pant, et al. Investigational New Drugs (2013) [ Paper ]
18Completed

For more information, please contact us at clinical@meipharma.com.